Biomerica stock rises after UAE health ministry approves kidney test Investing.com -- Biomerica Inc (NASDAQ:BMRA) stock rose 7% in premarket trading Wednesday after the company announced that the United Arab Emirates Ministry of Health and Prevention has approved its Fortel Kidney Test for home use. The diagnostic test detects low levels of albumin in urine, an early marker of kidney disease, in just 10 minutes. It is designed particularly for individuals with diabetes and hypertension, who face higher risks of developing chronic kidney disease. This regulatory approval represents a significant market opportunity for Biomerica in the UAE, where approximately one in four nationals have diabetes and about 31% of the population suffers from hypertension, according to a meta-analysis cited by the company. "The Fortel Kidney Test addresses a gap in preventative healthcare by allowing patients and physicians to detect kidney disease before symptoms appear," said Zack Irani, CEO of Biomerica. "With the high prevalence of diabetes and hypertension in the UAE, this approval supports our mission to bring life-saving diagnostic tools to communities where they are most needed." The company plans to make the test available in pharmacies, clinics, and hospitals throughout the UAE through partnerships with distributors and healthcare providers. This approval strengthens Biomerica’s presence in the Middle East, following the regional success of its EZ Detect Colon Disease Test. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. ProPicks AI evaluates BMRA alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if BMRA is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Click Subscribe #Biomerica #StockMarket #UAEHealth #KidneyHealth #Investing

Biomerica stock soars after UAE approves home H. pylori test Investing.com -- Biomerica Inc (NASDAQ:BMRA) stock surged 30.4% after the UAE Ministry of Health and Prevention approved the company’s Fortel Ulcer Test for home use in the country. The approval allows UAE residents to self-administer the 10-minute rapid diagnostic test that detects antibodies to Helicobacter pylori (H. pylori), a bacterium responsible for peptic ulcers and a significant portion of gastric cancer cases. H. pylori affects approximately 41% of the UAE population, with up to 20% of infected individuals potentially developing serious complications if left untreated. The World Health Organization has classified H. pylori as a Class 1 carcinogen and listed it among the top antibiotic-resistant bacterial threats. "With this home-use approval, we’re giving people direct access to a reliable tool for early detection of a dangerous infection that could result in serious complications," said Zack Irani, CEO of Biomerica. "This can help drive earlier and more effective medical treatment and potentially save lives." The company is now partnering with UAE-based distributors and healthcare providers to make the test available at pharmacies, clinics, and online platforms. This approval strengthens Biomerica’s presence in the Middle East, building on the previous regional launch of its EZ Detect Colon Disease Test. Biomerica focuses on delivering affordable diagnostic tools that improve patient outcomes through early disease detection. The company’s products are designed to be accessible and effective for global health improvement. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #Biomerica #Stocks #Investing #HPylori #UAE

#BMRA inFoods IBS achieves ~49% reduction in IBS symptoms like pain & bloating in real-world data! Personalized diet
#biomerica #inFoodsIBS #IBS
prismmarketview.com/biomericas-i...